Modified-Irinotecan/Fluorouracil/Levoleucovorin Therapy as Ambulatory Treatment for Metastatic Colorectal Cancer

Yuuki, S.; Fuse, Nozomu; Kato, Takashi; Miyagishima, Takuto; Kudo, Mineo; Watanabe, Masao; Tateyama, Masao; Kunieda, Y; Wakahama, Osamu; Sakata, Y.; Asaka, Masahiro

doi:10.2165/11534470-000000000-00000

Cited by 5 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the HGCSG focused on the safety of study subjects and decided to reduce the dose to 100 mg/m 2 in this study. Furthermore, the modified IFL regimen (irinotecan, 5-fluorouracil, leucovorin) that was evaluated in a study performed by the HGCSG [14] simultaneously with this study used 100 mg/m 2 irinotecan biweekly, and this dose showed equivalent efficacy to the IFL regimen reported by Saltz et al [15]. Therefore, the dose of irinotecan to be used in this study was set at 100 mg/m 2 .…”

Section: Methodsmentioning

confidence: 99%

Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302)

et al. 2011

Self Cite

View full text Add to dashboard Cite

Objectives: This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer. Methods: The response rate was the primary endpoint. Safety, progression-free survival time, and median survival time were secondary endpoints. The subjects were untreated patients with inoperable advanced colorectal cancer. Irinotecan was administered at a dose of 100 mg/m² (on days 1 and 15). S-1 (40 mg/m²) was administered for 2 weeks (on days 1 to 14) and followed by a 2-week rest. Results: Forty patients were enrolled. Four patients had grade 4 neutropenia, and six patients had grade 3 diarrhea. No other serious hematologic or nonhematologic adverse reactions occurred, and all patients received IRIS safely on an outpatient basis. The response rate was 52.5% (95% confidence interval [CI], 36.1–68.5%). Median progression-free survival was 8.6 months (95% CI, 5.3–11.9), and median survival time was 23.4 months (95% CI, 15.9–30.8). Conclusions: IRIS produced a high response rate and could be given safely. IRIS may become a first-line treatment for inoperable or recurrent advanced colorectal cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302)

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Type I topoisomerase (topo I) induces transient single-stranded breaks of the DNA duplex forming a reversible topo I-DNA covalent complex [24,25]. Stabilization of the cleavable complex brings cells to death and the cleavable complex formed by the human enzyme is the specific target of drugs belonging to the camptothecin family that are in clinical use in colorectal cancer and solid tumors treatment [26][27][28][29][30]. Most eukaryotic type IB topoisomerases are monomeric enzymes including human topoisomerase I, which is comprised of 765 amino acids (91 kDa).…”

Section: Introductionmentioning

confidence: 99%

Conjugated Eicosapentaenoic Acid (cEPA) Inhibits L. donovani Topoisomerase I and has an Antiproliferative Activity Against L. donovani Promastigotes

Desideri¹

2011

TOANTIMJ

View full text Add to dashboard Cite

Conjugated eicosapentaenoic acid inhibits the relaxation activity of purified L. donovani topoisomerase I, with an efficiency higher than that displayed by the corresponding human enzyme. Docking of the acid compound over the 3D structure of the enzyme shows that the complex is stabilized by a large network of interaction between the compound and many residues located in proximity of the active site, including the catalytic tyrosine 222, providing an explanation for its efficient inhibitory effect. The acid has also a strong antiprotozoal activity against L. donovani promastigotes ( EC 50 = 75 M) whilst it has no effect against murine macrophages (IC 50 2 mM). Taken together the results indicate that L. donovani topoisomerase I can be considered an interesting molecular target and that conjugated eicosapentaenoic acid can be taken in consideration as a possible lead compound against leishmaniasis.

show abstract

Synthesis, crystal structure and antitumor activity of a dinuclear calcium complex based on 1,5-naphthalenedisulfonate and 2,2′-bipyridine ligands

2014

View full text Add to dashboard Cite

Modified-Irinotecan/Fluorouracil/Levoleucovorin Therapy as Ambulatory Treatment for Metastatic Colorectal Cancer

Abstract: Modified-IFL therapy is a practical, effective and tolerable option for ambulatory treatment of advanced colorectal cancer.

Cited by 5 publications

References 25 publications

Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302)

Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302)

Conjugated Eicosapentaenoic Acid (cEPA) Inhibits L. donovani Topoisomerase I and has an Antiproliferative Activity Against L. donovani Promastigotes

Synthesis, crystal structure and antitumor activity of a dinuclear calcium complex based on 1,5-naphthalenedisulfonate and 2,2′-bipyridine ligands

Contact Info

Product

Resources

About